Atuka (Canada)

Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit

Karen L. Eskow Jaunarajs, David G. Standaert, Tacey X. Viegas et al. · Movement Disorders · 2013 · 68 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease

James B. Koprich, Susan H. Fox, Tom H. Johnston et al. · Movement Disorders · 2011 · 68 citations

Medicine, Neuroscience, Pharmacology +17

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque

James B. Koprich, Tom H. Johnston, Gabriela Reyes et al. · PLoS ONE · 2016 · 62 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease

Alexander Grotemeyer, Judith F. Fischer, James B. Koprich et al. · Journal of Neuroinflammation · 2023 · 40 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque

Tom H. Johnston, Philippe Huot, Susan H. Fox et al. · Neuropharmacology · 2013 · 38 citations

Medicine, Neuroscience, Pharmacology +15